ASCO GU 2022 - Results from #20

Viewing 21-40 of 316 articles

ASCO GU 2022: Radiation Therapy in Localized Disease: Changing Horizons

ASCO GU 2022: Quantitative Assessment of PSMA Imaging Before and After 177Lu-PSMA-617 Treatment in a Phase I/II Trial

ASCO GU 2022: PROTEUS: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Apalutamide plus ADT Versus Placebo plus ADT Prior to Radical Prostatectomy in Patients with Localized or Locally Advanced High-Risk Prostate Cancer

ASCO GU 2022: Prevalence and Natural History of Non-Metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis

ASCO GU 2022: Preliminary Results of the "DUO" Observational Study: Quality of Life Assessment and Cross-Sectional Follow-up of Prostate Cancer Patients Treated with Degarelix

ASCO GU 2022: Preferences and Perceptions of Patients with mCRPC for Treatments and Biomarker Testing: An International Qualitative Study

ASCO GU 2022: Phase 1b Study of Tarlatamab, a Half-Life Extended Bispecific T-Cell Engager (HLE BiTE Immune Therapy) Targeting DLL3, in De Novo or Treatment Emergent Neuroendocrine Prostate Cancer

ASCO GU 2022: Phase 1 study of PSCA-targeted CAR T cell therapy for mCRPC

ASCO GU 2022: Novel Framework for Treatment Response Evaluation Using PSMA-PET/CT in Patients with mCRPC (RECIP): An International Multicenter Study

ASCO GU 2022: The Changing Landscape of Treatment and Survival for Men with Castration-Resistant Prostate Cancer in the Era of Novel Treatments

ASCO GU 2022: Disparities in Prostate Cancer: An Ethnicity Comparative Focus Among Hispanic Americans Versus Non-Hispanic Whites

ASCO GU 2022: The Effects of a Preference-Based Exercise Trial on Outcomes in Men on Androgen Deprivation Therapy (ADT) for Prostate Cancer Compared to an Exercise Randomized Controlled Trial of the Same Interventions

ASCO GU 2022: Outcomes of an Advanced Practice Nurse (APN)-Led Cancer Genetics Service

ASCO GU 2022: Evaluation of Compliance of Next-Generation Sequencing (NGS) Testing in Stage IV Genitourinary (GU) Cancer Patients and the Effect of an EHR Prompt (EP) on Increasing Frequency

ASCO GU 2022: Phase 1 Study of PSCA-Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2022: Evaluating the Contribution of Virtual Peer-Led Support to Comprehensive Prostate Cancer (PCa ) Care: The AnCan Experience

ASCO GU 2022: Comparison of Major Adverse Cardiovascular Events Risk After Androgen Deprivation Therapy Initiation by Body Mass Index

ASCO GU 2022: Electronic Patient Reporting Outcomes Are a Promising Predictive Factor of Prostate Cancer Patient Survival: The Protecty Study

ASCO GU 2022: A Prospective Study of the Relationship Between CRPC Patient’s Quality of Life After Enzalutamide and Serum Testosterone Levels Measured via LC-MS/MS

ASCO GU 2022: Clinical Annotations for Prostate Cancer Research: Defining Data Elements, Creating a Reproducible Analytical Pipeline, and Assessing Data Quality

1
2
3
4
5
6
7
8
9
10